Kidney TransplantationTrasplanCEUNCT07923188
Online Exercise Program for Transplant Patients: A Pilot Study
A study testing Online Therapeutic Exercise Programme in people with Kidney Transplantation and Physical Function, run by Cardenal Herrera University at 1 site in Spain.
Trial summary
Kidney transplant recipients frequently experience reduced physical function, muscle weakness, low levels of physical activity, and an increased risk of cardiovascular and metabolic complications, despite improvements in survival and quality of life following transplantation. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Kidney Transplantation, Physical Function, Muscle Weakness Condition
- What is being tested?
- Online Therapeutic Exercise Programme
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteSpain
- Study dates
- 1 Nov 2026to 14 May 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 18 years or older.
- Kidney transplant recipients.
- At least 12 months post-transplantation.
- Sufficient cognitive capacity to understand study instructions and provide informed consent.
- Ability to monitor heart rate and blood pressure at home.
- Ability to connect remotely and participate in synchronous online exercise sessions.
Who cannot join
- Physical or clinical limitations that prevent safe participation in the exercise programme, such as severe cardiovascular instability.
- Severe psychopathology or serious cognitive impairment.
- Specific medical contraindications to participation in the exercise programme.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Kidney transplant recipients frequently experience reduced physical function, muscle weakness, low levels of physical activity, and an increased risk of cardiovascular and metabolic complications, despite improvements in survival and quality of life following transplantation. Therapeutic exercise has been shown to improve cardiorespiratory fitness, muscle strength, and physical function in this population. However, access to supervised rehabilitation programmes after transplantation remains limited. Online exercise programmes may provide an accessible and feasible alternative, particularly for patients who face geographical or logistical barriers to attending supervised in-person sessions.
Read the detailed description
This pilot randomized controlled trial aims to evaluate the feasibility and safety of a supervised group-based online therapeutic exercise programme for transplant recipients. Participants will be randomly allocated to either a control group receiving usual care or an intervention group participating in a supervised online exercise programme. Secondary outcomes will include muscle strength, physical function, physical activity, sarcopenia, frailty, muscle characteristics, anthropometric measures, body composition, and biochemical parameters.
- Being tested
- Online Therapeutic Exercise Programme, Usual Care Control Group
- Keywords
- Kidney transplantation, Therapeutic exercise, Online exercise, Muscle strength, Physical activity, Sarcopenia, Frailty
- Medical subject headings
- Motor Activity, Sarcopenia, Frailty
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Online Therapeutic Exercise ProgrammeBehavioural
Participants will complete three supervised online exercise sessions per week for 24 weeks. Each session will last approximately 30-40 minutes and will include lower-limb resistance exercises targeting the major muscle groups, brisk walking intervals, and progressive balance exercises. Exercise difficulty will be individualized by the physiotherapist according to perceived exertion. Heart rate, blood pressure, and rating of perceived exertion will be monitored during the intervention.
Usual Care Control GroupBehavioural
Participants randomized to the control group will maintain their usual activities and standard care throughout the 24-week intervention period. They will not receive the supervised online therapeutic exercise intervention.
| Study group | Role | What they receive |
|---|---|---|
| Online Exercise Group | Experimental | Participants allocated to the intervention group will participate in a supervised group-based online therapeutic exercise programme delivered via Microsoft Teams for 24 weeks. Receives: Behavioral: Online Therapeutic Exercise Programme |
| Usual Care Control Group | Active comparator | Participants allocated to the control group will continue with their usual activities and usual care throughout the 24-week study period and will not participate in the supervised online therapeutic exercise programme. Receives: Behavioral: Usual Care Control Group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Recruitment Rate
The percentage of eligible individuals who are enrolled in the study.
Measured: During the recruitment period, up to 2 months
Adherence to the Online Exercise Programme
Adherence will be calculated as the percentage of exercise sessions completed by each participant relative to the total number of sessions scheduled during the 24-week intervention.
Measured: Throughout the 24-week intervention
Participant Retention Rate
The percentage of enrolled participants who complete the final study assessment relative to the total number of participants initially enrolled.
Measured: At 24 weeks
Number of Adverse Events During the Exercise Programme
Safety will be assessed by recording adverse events occurring during exercise sessions, including musculoskeletal injuries, cardiovascular symptoms, exercise intolerance, or any event requiring modification or temporary suspension of the intervention.
Measured: Throughout the 24-week intervention
Secondary outcomes (25)
Lower-Limb Muscle Strength Assessed by Hand-Held Dynamometry
Maximal isometric strength of the hip flexors and hip abductors will be assessed using hand-held dynamometry. Three maximal voluntary contractions will be performed for each muscle group, and the maximum value will be recorded in kilogram-force (kgf).
Measured: Baseline, 4 weeks, 3 months, and 6 months
Handgrip Strength
Handgrip strength will be assessed using a Jamar® hydraulic dynamometer. Three maximal voluntary contractions will be performed with each hand, and the maximum value will be recorded in kilograms (kg).
Measured: Baseline, 3 months, and 6 months
60-Second Sit-to-Stand Test Performance
Functional capacity will be assessed using the 60-Second Sit-to-Stand Test (STS-60). The total number of complete sit-to-stand repetitions performed within 60 seconds will be recorded. A higher number of repetitions indicates better functional performance.
Measured: Baseline, 3 months, and 6 months
Timed Up and Go Test Performance
Functional mobility and dynamic balance will be assessed using the Timed Up and Go (TUG) test. The time required to stand from a chair, walk 3 metres, turn, return, and sit down will be recorded in seconds.
Measured: Baseline, 3 months, and 6 months
6-Minute Walk Test Distance
Walking capacity will be assessed using the 6-Minute Walk Test (6MWT). The total distance walked during 6 minutes will be recorded in metres (m).
Measured: Baseline, 3 months, and 6 months
Physical Activity Assessed by the Human Activity Profile
Physical activity will be assessed using the Human Activity Profile (HAP). The Adjusted Activity Score (AAS) will be recorded.
Measured: Baseline, 3 months, and 6 months
Change in Risk of Sarcopenia Assessed by SARC-F
Risk of sarcopenia will be assessed using the SARC-F questionnaire. The total score ranges from 0 to 10, with a score ≥4 indicating risk of sarcopenia.
Measured: Baseline, 3 months, and 6 months
Frailty Assessed by the FRAIL Scale
Frailty will be assessed using the FRAIL scale. Scores range from 0 to 5, with a score ≥3 indicating frailty.
Measured: Baseline, 3 months, and 6 months
Rectus Femoris Muscle Characteristics Assessed by Ultrasound
Musculoskeletal ultrasound will be used to assess rectus femoris muscle thickness (mm), cross-sectional area (cm²), and muscle echogenicity.
Measured: Baseline, 3 months, and 6 months
Anthropometric Measurements
Waist circumference, upper-arm circumference, and calf circumference will be measured using standardised procedures and recorded in centimetres (cm).
Measured: Baseline, 3 months, and 6 months
Body Composition Assessed by Bioelectrical Impedance Vector Analysis
Body composition will be assessed using bioelectrical impedance vector analysis (BIVA), including muscle mass.
Measured: Baseline, 3 months, and 6 months
T3
Triiodothyronine (T3) is the primary biologically active form of thyroid signaling molecules. Measures both bound and free T3 combined. (ng/dL)
Measured: Baseline, 3 months, and 6 months
T4
Thyroxine (T4) is one of the two main hormones produced by the thyroid gland.(mcg/dL)
Measured: Baseline, 3 months, and 6 months
Testosterone
Testosterone is the primary male sex hormone (androgen), although it is also present and essential in females in much smaller amounts. It is a steroid hormone synthesized primarily from cholesterol; (ng/dL :nanograms per deciliter)
Measured: Baseline, 3 months, and 6 months
Cortisol
Cortisol is a steroid hormone produced by the adrenal glands (located on top of each kidney) that is essential for life and regulates a wide range of vital processes throughout the body.
Measured: Baseline, 3 months, and 6 months
Estrogens
Estrogens are a group of hormones crucial for sexual and reproductive development, primarily in women.Estrogen levels are typically measured via a blood test and reported in picograms per milliliter (pg/mL) or picomoles per liter (pmol/L).
Measured: Baseline, 3 months, and 6 months
Progesterone
Progesterone is an endogenous 21-carbon steroid hormone derived from cholesterol. It is primarily classified as a progestogen (the main one in the human body) and plays a fundamental role in regulating the menstrual cycle, supporting early pregnancy, and promoting embryogenesis.
Measured: Baseline, 3 months, and 6 months
Fasting glucose
Fasting glucose (glicemia a digiuno) is a blood test that measures the amount of sugar (glucose) in your blood after an overnight fast (usually 8 to 12 hours without eating or drinking anything except water). It is primarily used to screen for and diagnose prediabetes and diabetes.Fasting glucose is typically measured in milligrams per deciliter (mg/dL) or millimoles per liter (mmol/L).
Measured: Baseline, 3 months, and 6 months
Creatinine
Creatinine is a waste product produced by muscles from the breakdown of a compound called creatine. Your kidneys filter creatinine from your blood and excrete it through urine. Measuring creatinine levels is the most common way to assess how well your kidneys are functioning.Milligrams per deciliter (mg/dL).
Measured: Baseline, 3 months, and 6 months
Estimated glomerular filtration rate
The Estimated Glomerular Filtration Rate (eGFR) is a blood test that estimates how well your kidneys are filtering waste. It is the primary metric used by medical professionals to determine your level of kidney function and to stage Chronic Kidney Disease (CKD). The measurement is reported in milliliters per minute per 1.73 square meters of body surface area (mL/min/1.73 m²).
Measured: Baseline, 3 months, and 6 months
C-reactive protein
C-reactive protein (CRP) is a protein made by the liver that increases when there is active inflammation or infection in the body.CRP is typically measured in milligrams per liter (mg/L) or milligrams per deciliter (mg/dL).
Measured: Baseline, 3 months, and 6 months
Albumin
Albumin is the most abundant circulating protein found in blood plasma, representing about 50% to 60% of all plasma proteins. Synthesized exclusively by the liver, it performs two vital biological functions: maintaining oncotic pressure (which keeps fluid from leaking out of blood vessels into surrounding tissues) and transporting molecules like hormones, fatty acids, bilirubin, medications, and ions throughout the body. Normal Adult Reference Range: 3.4 to 5.4 g/dL (grams per deciliter) or 34 to 54 g/L (grams per liter).
Measured: Baseline, 3 months, and 6 months
Total cholesterol
Total cholesterol is a measurement of the total amount of cholesterol in your blood. It is a waxy, fat-like substance that your body needs to build healthy cells, but having too much of it can increase your risk of heart disease.mg/dL (milligrams per deciliter).
Measured: Baseline, 3 months, and 6 months
A Complete Blood Count (CBC)
A Complete Blood Count (CBC) is a standard blood test that evaluates your overall health and detects a wide range of disorders, including anemia, infection, and leukemia. It measures the three primary types of cells in your blood: red blood cells, white blood cells, and platelets.
Measured: Baseline, 3 months, and 6 months
Albuminuria
Albuminuria is a pathological condition characterized by the abnormal presence of albumin-a primary plasma protein-in the urine. (mg/day)
Measured: Baseline, 3 months, and 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2026
- Study start1 Nov 2026 (estimated)
- Primary completion14 May 2027 (estimated)
- Study completion14 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Kidney TransplantationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cardenal Herrera University
- Sponsor type
- University, hospital or other
- Collaborators
- Hospital Universitario La Fe
- Responsible party
- Principal investigator, Eva Segura Ortí, Cardenal Herrera University
- Investigators
- Eva Segura-Ortí, PhD, Principal investigator, Universities Cardenal Herrera CEU
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07923188
- Sponsor's protocol ID
- TrasplanCEU
- Acronym
- TrasplanCEU
- Status last verified
- Oct 2026
- First submitted
- 26 Oct 2026
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Wang W. Optimizing Quality of Life in Kidney Transplant Recipients Through Structured Exercise: A Systematic Review and Evidence-Based Guidelines. Med Sci Monit. 2024 Jul 24;30:e943617. doi: 10.12659/MSM.943617.
PubMed 39044393Pape L, Boeck HT, Boyen J, Nohre M, Schiffer L, Kuck M, Schieffer E, Albrecht A, de Zwaan M, Tegtbur U, Schiffer M, Haufe S. Physical activity and exercise performance in patients after kidney transplantation - Data from the prospective KTx360 degrees aftercare program. J Sci Med Sport. 2025 Nov;28(11):938-945. doi: 10.1016/j.jsams.2025.06.012. Epub 2025 Jul 5.
PubMed 40681408Knobbe TJ, Kremer D, Zelle DM, Klaassen G, Dijkema D, van Vliet IMY, Leurs PB, Bemelman FJ, Christiaans MHL, Berger SP, Navis G, Bakker SJL, Corpeleijn E. Effect of an exercise intervention or combined exercise and diet intervention on health-related quality of life-physical functioning after kidney transplantation: the Active Care after Transplantation (ACT) multicentre randomised controlled trial. Lancet Healthy Longev. 2024 Sep;5(9):100622. doi: 10.1016/j.lanhl.2024.07.005. Epub 2024 Sep 10.
PubMed 39270688Billany RE, Macdonald JH, Burns S, Chowdhury R, Ford EC, Mubaarak Z, Sohansoha GK, Vadaszy N, Young HML, Bishop NC, Smith AC, Graham-Brown MPM. A structured, home-based exercise programme in kidney transplant recipients (ECSERT): A randomised controlled feasibility study. PLoS One. 2025 Feb 24;20(2):e0316031. doi: 10.1371/journal.pone.0316031. eCollection 2025.
PubMed 39992959doi:10.1080/0886022X.2025.2480246
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Online Exercise Program for Transplant Patients: A Pilot Study
- ClinicalTrials.gov ID
- NCT07923188
- Acronym / sponsor ID
- TrasplanCEU / TrasplanCEU
- Keywords
- Kidney transplantation, Therapeutic exercise, Online exercise, Muscle strength, Physical activity, Sarcopenia, Frailty
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Cardenal Herrera UniversityUniversity, hospital or other
- Collaborators
- Hospital Universitario La Fe
- Study start
- 1 Nov 2026 (estimated)
- Primary completion
- 14 May 2027 (estimated)
- Study completion
- 14 May 2027 (estimated)
- First posted
- 6 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Kidney transplant recipients frequently experience reduced physical function, muscle weakness, low levels of physical activity, and an increased risk of cardiovascular and metabolic complications, despite improvements in survival and quality of life following transplantation. Therapeutic exercise has been shown to improve cardiorespiratory fitness, muscle strength, and physical function in this population. However, access to supervised rehabilitation programmes after transplantation remains limited. Online exercise programmes may provide an accessible and feasible alternative, particularly for patients who face geographical or logistical barriers to attending supervised in-person sessions.
Detailed description
This pilot randomized controlled trial aims to evaluate the feasibility and safety of a supervised group-based online therapeutic exercise programme for transplant recipients. Participants will be randomly allocated to either a control group receiving usual care or an intervention group participating in a supervised online exercise programme. Secondary outcomes will include muscle strength, physical function, physical activity, sarcopenia, frailty, muscle characteristics, anthropometric measures, body composition, and biochemical parameters.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Online Exercise Group | Experimental | Behavioral: Online Therapeutic Exercise ProgrammeParticipants allocated to the intervention group will participate in a supervised group-based online therapeutic exercise programme delivered via Microsoft Teams for 24 weeks. |
| Usual Care Control Group | Active comparator | Behavioral: Usual Care Control GroupParticipants allocated to the control group will continue with their usual activities and usual care throughout the 24-week study period and will not participate in the supervised online therapeutic exercise programme. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Adults aged 18 years or older.
- Kidney transplant recipients.
- At least 12 months post-transplantation.
- Sufficient cognitive capacity to understand study instructions and provide informed consent.
- Ability to monitor heart rate and blood pressure at home.
Key exclusion criteria (3 listed)
- Physical or clinical limitations that prevent safe participation in the exercise programme, such as severe cardiovascular instability.
- Severe psychopathology or serious cognitive impairment.
- Specific medical contraindications to participation in the exercise programme.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Online Therapeutic Exercise ProgrammeParticipants will complete three supervised online exercise sessions per week for 24 weeks. Each session will last approximately 30-40 minutes and will include lower-limb resistance exercises targeting the major muscle groups, brisk walking intervals, and progressive balance exercises. Exercise difficulty will be individualized by the physiotherapist according to perceived exertion. Heart rate, blood pressure, and rating of perceived exertion will be monitored during the intervention. | Behavioural | Online Exercise Group |
| Usual Care Control GroupParticipants randomized to the control group will maintain their usual activities and standard care throughout the 24-week intervention period. They will not receive the supervised online therapeutic exercise intervention. | Behavioural | Usual Care Control Group |
Primary outcome
Recruitment Rate
Time frame: During the recruitment period, up to 2 months
The percentage of eligible individuals who are enrolled in the study.
Adherence to the Online Exercise Programme
Time frame: Throughout the 24-week intervention
Adherence will be calculated as the percentage of exercise sessions completed by each participant relative to the total number of sessions scheduled during the 24-week intervention.
Participant Retention Rate
Time frame: At 24 weeks
The percentage of enrolled participants who complete the final study assessment relative to the total number of participants initially enrolled.
Number of Adverse Events During the Exercise Programme
Time frame: Throughout the 24-week intervention
Safety will be assessed by recording adverse events occurring during exercise sessions, including musculoskeletal injuries, cardiovascular symptoms, exercise intolerance, or any event requiring modification or temporary suspension of the intervention.
25 secondary outcomes
Lower-Limb Muscle Strength Assessed by Hand-Held Dynamometry
Time frame: Baseline, 4 weeks, 3 months, and 6 months
Handgrip Strength
Time frame: Baseline, 3 months, and 6 months
60-Second Sit-to-Stand Test Performance
Time frame: Baseline, 3 months, and 6 months
Timed Up and Go Test Performance
Time frame: Baseline, 3 months, and 6 months
6-Minute Walk Test Distance
Time frame: Baseline, 3 months, and 6 months
Physical Activity Assessed by the Human Activity Profile
Time frame: Baseline, 3 months, and 6 months
Change in Risk of Sarcopenia Assessed by SARC-F
Time frame: Baseline, 3 months, and 6 months
Frailty Assessed by the FRAIL Scale
Time frame: Baseline, 3 months, and 6 months
Rectus Femoris Muscle Characteristics Assessed by Ultrasound
Time frame: Baseline, 3 months, and 6 months
Anthropometric Measurements
Time frame: Baseline, 3 months, and 6 months
Body Composition Assessed by Bioelectrical Impedance Vector Analysis
Time frame: Baseline, 3 months, and 6 months
T3
Time frame: Baseline, 3 months, and 6 months
T4
Time frame: Baseline, 3 months, and 6 months
Testosterone
Time frame: Baseline, 3 months, and 6 months
Cortisol
Time frame: Baseline, 3 months, and 6 months
Estrogens
Time frame: Baseline, 3 months, and 6 months
Progesterone
Time frame: Baseline, 3 months, and 6 months
Fasting glucose
Time frame: Baseline, 3 months, and 6 months
Creatinine
Time frame: Baseline, 3 months, and 6 months
Estimated glomerular filtration rate
Time frame: Baseline, 3 months, and 6 months
C-reactive protein
Time frame: Baseline, 3 months, and 6 months
Albumin
Time frame: Baseline, 3 months, and 6 months
Total cholesterol
Time frame: Baseline, 3 months, and 6 months
A Complete Blood Count (CBC)
Time frame: Baseline, 3 months, and 6 months
Albuminuria
Time frame: Baseline, 3 months, and 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Background: PubMed 39044393Wang W. Optimizing Quality of Life in Kidney Transplant Recipients Through Structured Exercise: A Systematic Review and Evidence-Based Guidelines. Med Sci Monit. 2024 Jul 24;30:e943617. doi: 10.12659/MSM.943617.
- Background: PubMed 40681408Pape L, Boeck HT, Boyen J, Nohre M, Schiffer L, Kuck M, Schieffer E, Albrecht A, de Zwaan M, Tegtbur U, Schiffer M, Haufe S. Physical activity and exercise performance in patients after kidney transplantation - Data from the prospective KTx360 degrees aftercare program. J Sci Med Sport. 2025 Nov;28(11):938-945. doi: 10.1016/j.jsams.2025.06.012. Epub 2025 Jul 5.
- Background: PubMed 39270688Knobbe TJ, Kremer D, Zelle DM, Klaassen G, Dijkema D, van Vliet IMY, Leurs PB, Bemelman FJ, Christiaans MHL, Berger SP, Navis G, Bakker SJL, Corpeleijn E. Effect of an exercise intervention or combined exercise and diet intervention on health-related quality of life-physical functioning after kidney transplantation: the Active Care after Transplantation (ACT) multicentre randomised controlled trial. Lancet Healthy Longev. 2024 Sep;5(9):100622. doi: 10.1016/j.lanhl.2024.07.005. Epub 2024 Sep 10.
- Background: PubMed 39992959Billany RE, Macdonald JH, Burns S, Chowdhury R, Ford EC, Mubaarak Z, Sohansoha GK, Vadaszy N, Young HML, Bishop NC, Smith AC, Graham-Brown MPM. A structured, home-based exercise programme in kidney transplant recipients (ECSERT): A randomised controlled feasibility study. PLoS One. 2025 Feb 24;20(2):e0316031. doi: 10.1371/journal.pone.0316031. eCollection 2025.
- Backgrounddoi:10.1080/0886022X.2025.2480246
- Individual participant dataSharing planned: Undecided
Related trials for Kidney Transplantation
RecruitingPhase 2
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
Antibody-Mediated Rejection (AMR)
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Not yet recruitingEarly Phase 1
Biomarker-Guided Mycophenolate Mofetil Elimination in Low-Risk Older Adult Kidney Transplant Recipients
Kidney Transplant Recipient
Recruiting
Non-Invasive Monitoring of Pediatric Kidney Transplant Recipients and Immunosuppression Personalization: an Open-labeled Multicenter Randomized Controlled Study
Pediatric Kidney Disease, Transplant;Failure,Kidney
Not yet recruitingPhase 2
(TNX-1500) in Kidney Transplant Recipients
Kidney Transplant, Kidney Transplant Failure and Rejection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Eva Segura-Ortí, PhD principal investigator
Universities Cardenal Herrera CEU
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Online Therapeutic Exercise Programme in people with Kidney Transplantation and Physical Function, run by Cardenal Herrera University at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Recruitment Rate (time frame: During the recruitment period, up to 2 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07923188, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.